Dogwood Therapeutics DWTX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Dogwood Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dogwood Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dogwood Therapeutics's operating cash flow?
- Dogwood Therapeutics (DWTX) reported operating cash flow of -$4.59M in Q1 2026.
- How has Dogwood Therapeutics's operating cash flow changed year-over-year?
- Dogwood Therapeutics's operating cash flow increased by 2.0% year-over-year, from -$4.68M to -$4.59M.
- What is the long-term trend for Dogwood Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Dogwood Therapeutics's operating cash flow has grown at a -0.1% compound annual growth rate (CAGR), from -$15.69M to -$15.62M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.